Example: Heart Attack

Search clinical trials for: FOLFIRI

Total 164 results

NCT03959293

Active, not recruiting

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Conditions: Gastric Adenocarcinoma, Gastric Cancer
NCT04256707

Recruiting

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Conditions: Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
NCT04793958

Recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer
NCT04926545

Not yet recruiting

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Conditions: Malignant Tumor, Diarrhea
NCT02181556

Completed

Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer
NCT02820857

Recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Conditions: Neuroendocrine Carcinomas
NCT03331640

Active, not recruiting

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
NCT04270929

Withdrawn

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

Conditions: Pancreatic Adenocarcinoma
NCT03798626

Recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Conditions: Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
NCT03082209

Recruiting

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Conditions: Advanced Solid Tumors, Cancer, Hematologic Malignancies
NCT03250832

Active, not recruiting

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Conditions: Neoplasms
NCT03253133

Completed

Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC

Conditions: Colorectal Cancer
NCT03186326

Active, not recruiting

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Conditions: Metastatic Colorectal Cancer, MSI
NCT01946074

Active, not recruiting

A Study of ABT-165 in Subjects With Solid Tumors

Conditions: Advanced Solid Tumors
NCT03829410

Recruiting

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Conditions: Metastatic Colorectal Cancer, KRAS Gene Mutation
NCT02942706

Not yet recruiting

Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC

Conditions: Colorectal Cancer
NCT04554836

Recruiting

MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
NCT03286738

Recruiting

Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer
NCT03635021

Recruiting

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Conditions: Colorectal Cancer
NCT03081143

Recruiting

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Conditions: Advanced Gastric or EGJ Cancer
NCT04810585

Recruiting

Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Conditions: Recurrent or Metastatic Colorectal Cancer
NCT04553692

Recruiting

Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers

Conditions: Solid Tumor, Colorectal Cancer, Gastric Cancer, Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer, Sarcoma
NCT02563002

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Conditions: Colorectal Carcinoma
NCT03597581

Recruiting

A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, Pancreatic Cancer, Pancreatic Neoplasm
NCT00066274

Completed

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Conditions: Colorectal Cancer